메뉴 건너뛰기




Volumn 60, Issue 1, 2014, Pages 56-64

All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; LEDIPASVIR; PEGINTERFERON ALPHA2A; RIBAVIRIN; TEGOBUVIR; VEDROPREVIR; VIRUS RNA;

EID: 84903301263     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27053     Document Type: Article
Times cited : (43)

References (14)
  • 3
    • 84879689088 scopus 로고    scopus 로고
    • 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
    • Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 2013;13:535-542.
    • (2013) Nat Rev Immunol , vol.13 , pp. 535-542
    • Heim, M.H.1
  • 4
    • 84880588592 scopus 로고    scopus 로고
    • A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir
    • Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, et al. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol 2013;11:1014-1020.
    • (2013) Clin Gastroenterol Hepatol , vol.11 , pp. 1014-1020
    • Chen, E.Y.1    Sclair, S.N.2    Czul, F.3    Apica, B.4    Dubin, P.5    Martin, P.6
  • 6
    • 81855228070 scopus 로고    scopus 로고
    • Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
    • Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011;141:2047-2055.
    • (2011) Gastroenterology , vol.141 , pp. 2047-2055
    • Zeuzem, S.1    Asselah, T.2    Angus, P.3    Zarski, J.P.4    Larrey, D.5    Mullhaupt, B.6
  • 7
    • 84862684876 scopus 로고    scopus 로고
    • A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
    • Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012;57:24-31.
    • (2012) J Hepatol , vol.57 , pp. 24-31
    • Lawitz, E.J.1    Gruener, D.2    Hill, J.M.3    Marbury, T.4    Moorehead, L.5    Mathias, A.6
  • 9
    • 78751633456 scopus 로고    scopus 로고
    • Antiviral response and resistance analysis of treatment-naïve HCV infected subjects receiving single and multiple doses of GS-9190 [Abstract]
    • Harris J, Bae A, Sun S, Svarovskaia E, Miller M, Mo H. Antiviral response and resistance analysis of treatment-naïve HCV infected subjects receiving single and multiple doses of GS-9190 [Abstract]. Hepatology 2010;52(Suppl):772A.
    • (2010) Hepatology , vol.52 , Issue.SUPPL
    • Harris, J.1    Bae, A.2    Sun, S.3    Svarovskaia, E.4    Miller, M.5    Mo, H.6
  • 10
    • 84881311392 scopus 로고    scopus 로고
    • The NS5A inhibitor GS-5885 is safe and well tolerated in more than 1000 patients treated in phase 2 studies [Abstract]
    • Everson GT, Lawitz E, Thompson A, Sulkowski M, Zhu Y, Brainard D, et al. The NS5A inhibitor GS-5885 is safe and well tolerated in more than 1000 patients treated in phase 2 studies [Abstract]. Hepatology 2012;56(Suppl):572A.
    • (2012) Hepatology , vol.56 , Issue.SUPPL
    • Everson, G.T.1    Lawitz, E.2    Thompson, A.3    Sulkowski, M.4    Zhu, Y.5    Brainard, D.6
  • 11
    • 84877782905 scopus 로고    scopus 로고
    • Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
    • Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-1455.
    • (2013) Gastroenterology , vol.144 , pp. 1450-1455
    • Chen, J.1    Florian, J.2    Carter, W.3    Fleischer, R.D.4    Hammerstrom, T.S.5    Jadhav, P.R.6
  • 12
    • 80054928558 scopus 로고    scopus 로고
    • In vitro studies on the potential for the hepatitis c virus protease inhibitors GS-9256 and GS-9451 to affect bilirubin elimination [Abstract]
    • Tong L, Mwangi J, Roy A, Murray B, Delaney W, Yang C, et al. In vitro studies on the potential for the hepatitis c virus protease inhibitors GS-9256 and GS-9451 to affect bilirubin elimination [Abstract]. J Hepatol 2011;54(Suppl):S487.
    • (2011) J Hepatol , vol.54 , Issue.SUPPL
    • Tong, L.1    Mwangi, J.2    Roy, A.3    Murray, B.4    Delaney, W.5    Yang, C.6
  • 14
    • 77950601553 scopus 로고    scopus 로고
    • Hepatitis C treatment completion rates in routine clinical care
    • Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010;30:240-250.
    • (2010) Liver Int , vol.30 , pp. 240-250
    • Butt, A.A.1    McGinnis, K.A.2    Skanderson, M.3    Justice, A.C.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.